URL has been copied successfully!
In a setback for Merck, a Dutch court ruled that the company infringed on a patent pertaining to a subcutaneous formulation of its Keytruda cancer treatment and was ordered to halt manufacturing and marketing the medication in several European countries, including France, Italy, Sweden, Switzerland, and the Netherlands.
The ruling came as part of a widening patent infringement dispute with Halozyme Therapeutics over the best-selling cancer treatment. Patients requiring Keytruda will still have access to the existing intravenous version, which is not affected by the patent dispute or court order.
We asked Merck for comment and will update you accordingly.
Please follow us:
